Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980491641> ?p ?o ?g. }
- W2980491641 endingPage "925" @default.
- W2980491641 startingPage "913" @default.
- W2980491641 abstract "Introduction: The treatment of psoriasis with conventional topical therapies and disease-modifying anti-rheumatic drugs (DMARDs) is often linked to unsatisfactory outcomes and the risk of serious adverse events. Over the last decades, research advances in understanding the role of tumor necrosis factor alpha (TNF α) and other cytokines in the pathogenesis of psoriasis have driven the introduction of biologic agents targeting specific immune mediators in everyday clinical practice. TNF α inhibitors are a consolidated treatment option for patients with moderate-to-severe disease with remarkable efficacy and a reassuring safety profile.Areas covered: The PubMed database was searched using combinations of the following keywords: psoriasis, TNF α inhibitors, biologic therapy, pharmacodynamics, adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, adverse effects. The aim of this review is to describe the pharmacodynamic profile of anti-TNF α inhibitors, currently approved by the European Medicines Agency (EMA) for the treatment of psoriasis, focusing on related clinical implications, also in comparison to the new generation biological therapies targeting the interleukin 23/interleukin 17 axis.Expert opinion: Pharmacodynamics of TNF α inhibitors should be fully considered in planning patient’s therapy strategies, especially in case of secondary failures, poor adherence to treatment, instable psoriasis, high risk of infection, pregnant or lactating women, metabolic comorbidities, coexistence of other immune-mediated inflammatory diseases." @default.
- W2980491641 created "2019-10-25" @default.
- W2980491641 creator A5025788427 @default.
- W2980491641 creator A5028409198 @default.
- W2980491641 creator A5031189576 @default.
- W2980491641 creator A5068358573 @default.
- W2980491641 creator A5082014965 @default.
- W2980491641 creator A5088924737 @default.
- W2980491641 date "2019-10-29" @default.
- W2980491641 modified "2023-10-16" @default.
- W2980491641 title "Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis" @default.
- W2980491641 cites W1515219927 @default.
- W2980491641 cites W1527213440 @default.
- W2980491641 cites W1551371618 @default.
- W2980491641 cites W1570492102 @default.
- W2980491641 cites W1598998726 @default.
- W2980491641 cites W1701993624 @default.
- W2980491641 cites W1788977473 @default.
- W2980491641 cites W183089507 @default.
- W2980491641 cites W1842002390 @default.
- W2980491641 cites W1892676932 @default.
- W2980491641 cites W1929307843 @default.
- W2980491641 cites W1964215887 @default.
- W2980491641 cites W1964495712 @default.
- W2980491641 cites W1965067289 @default.
- W2980491641 cites W1969991375 @default.
- W2980491641 cites W1971364292 @default.
- W2980491641 cites W1971460377 @default.
- W2980491641 cites W1972188754 @default.
- W2980491641 cites W1973354423 @default.
- W2980491641 cites W1977385433 @default.
- W2980491641 cites W1982961586 @default.
- W2980491641 cites W1983004971 @default.
- W2980491641 cites W1985118454 @default.
- W2980491641 cites W1986539381 @default.
- W2980491641 cites W1986828908 @default.
- W2980491641 cites W1989219560 @default.
- W2980491641 cites W1989324269 @default.
- W2980491641 cites W1990625103 @default.
- W2980491641 cites W1992994203 @default.
- W2980491641 cites W1993586732 @default.
- W2980491641 cites W1997106678 @default.
- W2980491641 cites W1997353241 @default.
- W2980491641 cites W1997834526 @default.
- W2980491641 cites W2000851235 @default.
- W2980491641 cites W2003164428 @default.
- W2980491641 cites W2006048924 @default.
- W2980491641 cites W2006566213 @default.
- W2980491641 cites W2006783956 @default.
- W2980491641 cites W2006984401 @default.
- W2980491641 cites W2011473488 @default.
- W2980491641 cites W2012285680 @default.
- W2980491641 cites W2013275346 @default.
- W2980491641 cites W2013877744 @default.
- W2980491641 cites W2015347941 @default.
- W2980491641 cites W2015381888 @default.
- W2980491641 cites W2017720269 @default.
- W2980491641 cites W2018771885 @default.
- W2980491641 cites W2018798171 @default.
- W2980491641 cites W2020915788 @default.
- W2980491641 cites W2021225630 @default.
- W2980491641 cites W2024145785 @default.
- W2980491641 cites W2030605573 @default.
- W2980491641 cites W2031172875 @default.
- W2980491641 cites W2031504111 @default.
- W2980491641 cites W2033081114 @default.
- W2980491641 cites W2035027737 @default.
- W2980491641 cites W2036601710 @default.
- W2980491641 cites W2038835308 @default.
- W2980491641 cites W2039270725 @default.
- W2980491641 cites W2042093007 @default.
- W2980491641 cites W2044465471 @default.
- W2980491641 cites W2045317929 @default.
- W2980491641 cites W2045492445 @default.
- W2980491641 cites W2047000833 @default.
- W2980491641 cites W2047388295 @default.
- W2980491641 cites W2048814278 @default.
- W2980491641 cites W2051893297 @default.
- W2980491641 cites W2053582742 @default.
- W2980491641 cites W2062156425 @default.
- W2980491641 cites W2063627867 @default.
- W2980491641 cites W2065307318 @default.
- W2980491641 cites W2066015053 @default.
- W2980491641 cites W2068341153 @default.
- W2980491641 cites W2069009667 @default.
- W2980491641 cites W2069346187 @default.
- W2980491641 cites W2069571875 @default.
- W2980491641 cites W2070353058 @default.
- W2980491641 cites W2072738451 @default.
- W2980491641 cites W2072926000 @default.
- W2980491641 cites W2075994714 @default.
- W2980491641 cites W2078335647 @default.
- W2980491641 cites W2081839533 @default.
- W2980491641 cites W2083999893 @default.
- W2980491641 cites W2087369280 @default.
- W2980491641 cites W2087777607 @default.
- W2980491641 cites W2087934013 @default.
- W2980491641 cites W2092190921 @default.